December 10, 2015: Breathe Out

By Ramy Mahmoud at OptiNose

 

Despite affecting millions of people worldwide, treatments for serious nasal conditions have been limited by their inability to target the required site of action. Could new exhalation technologies hold the answer?

Within the broad category of respiratory technology, innovation focused on the nose, rather than the lungs, has been relatively overlooked. For many years, patients have suffered from a lack of advancement in this space, forced to rely mostly on the existing nasal spray devices that provide unsophisticated treatment delivery that works for simpler and milder applications like seasonal allergies.  This often falls short for more serious nasal conditions like chronic sinus disease, or more complex situations, including efforts to deliver drugs to the brain. Though certainly not the only application, one of the most obvious values of improving nasal delivery is to enable better treatment of diseases that reside deep in the nose.

This article is taken from Innovations in Pharmaceutical Technology, December 2015 issue, pages 18-21. © Samedan Ltd

Download (111KB PDF)


March 7, 2015: Evolving Past the Innovation Status Quo

WIRED | OptiNose
By Peter Miller, CEO, OptiNose

A decade ago, the accepted approach to innovation in the healthcare / pharmaceutical sector was a (relatively) straightforward one: invest heavily in R&D, discover new molecules, shepherd them through years of testing and regulatory approvals, and cross your fingers that in the end all goes well and you have a product that can generate a positive ROI. Consider that a recent Tufts Center study pegged the average cost of bringing a drug to market at just under $2.6 billion and the average success rate for a new molecule eventually receiving approval is approximately 0.01% — significantly worse odds than succeeding as a restaurant entrepreneur, where just about everyone fails.

Download (132KB PDF)


October 10, 2005: Breath-Actuated Bi-Directional Delivery Sets the Nasal Market on a New Course

OnDrug Delivery | OptiNose

Nasal drug delivery is already a thriving market but there is still a wide gap between what has been achieved in the past and what could be achieved were the full potential of this highly attractive administration route released. This article describes a technological breakthrough by OptiNose that has allowed the company to make that hitherto elusive step of achieving truly optimal nasal drug delivery. Compiled by ONdrugDelivery on behalf of OptiNose.

Download (985KB PDF)


September 10, 2004: Bi-Directional Nasal Device Delivers Drug on Exhalation

Pharmaceutical Technology | OptiNose

Traditional nasal spray pumps face a common challenge: they cannot efficiently deliver drug to the regions of the nasal passages where diseases originate. To address this problem, OptiNose has developed a patented bi-directional delivery system that can target the olfactory region.

Download (827KB PDF)


July 10, 2004: Bi-Directional Nasal Drug Delivery

Innovations in Pharmaceutical Technology | OptiNose

A new concept in nasal drug delivery looks set to transform the delivery efficiency of nasal spray products. A revolutionary new technology is expected to have a dramatic impact on the delivery of drugs via the nasal route. Traditionally, the development of nasal spray products has been faced with a major dilemma: on the one hand, nasal delivery can be improved by using smaller particles, but on the other, this has to be balanced against the increased risk of drug being inhaled into the lungs. A new concept, bi-directional drug delivery, addresses this dilemma by isolating the nasal circuit from the lungs – enabling particle size, flow rate and direction to be optimized.

Download (990KB PDF)


October 7, 2003: Who Nose How Far Nasal Delivery Can Go?

EPC | OptiNose

Nasal delivery has traditionally been restricted to topically acting substances used to treat the common cold and nasal allergies. Recently, however, there has been increased interest in the nose as an alternative to oral delivery and injection for many systemic drugs and vaccines. The highly vascularized and immunogenic nasal mucosa offers potential advantages in terms of quick action, improved bio-availability and patient compliance as well as improved immune response for vaccines. European Pharmaceutical Contractor, Autumn 2003.

Download (443KB PDF)


January 29, 2003: Nothing to Sneeze At

Pharmaceutical Formulation & Quality Magazine | OptiNose
Compiled by Cindy H. Dubin

Often overlooked and long neglected, the nose has become one of the most viable drug delivery pathways for treating everything from the flu to erectile dysfunction. The portal to our blood system is how nasal drug delivery experts view the nose. With the continuous development of more potent and complex molecules and the imminent expiration of many patents for major brands, novel delivery systems offer opportunities for developmental and marketed compounds alike. Nasal delivery is ideal for potent drugs that are to be delivered in small doses, as low as tens of milligrams. Copyrighted material, reprinted with permission from Pharmaceutical Formulation & Quality Magazine, June/July 2002 issue. For more information, visit www.pharmaquality.com. Reprint of full format article in pdf-format. Compiled by CINDY H.DUBIN.

Download (1MB PDF)


January 29, 2003: Nasal Delivery of Vaccines

EPC | OptiNose

Recently nasal delivery of vaccines has emerged as an attractive alternative to injection. Nasal vaccination elicits a local immune response and protection in addition to the systemic response. The mucosal immune response is rapid and nasal vaccines may induce protection in distant mucosal sites in the gut and uro-gentital tract as well. Proper formulation and adequate distribution to the nasal mucosa are essential for the efficiency and safety of mucosal vaccines. The complex nasal geometry represents a major challenge for efficient intranasal vaccination. Current delivery devices may prove inadequate to meet the future requirements for safe and reliable nasal vaccination. With permission from Pharmaceutical Manufacturing and Packing Sourcer.

Download (330KB PDF)